Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Credit agrmnt [a]
Appointed director
Kadmon Holdings, Inc. (KDMN) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/14/2022 SC 13G/A Point72 Asset Management, L.P. reports a 0% stake in Kadmon Holdings, Inc.
11/19/2021 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
11/16/2021 EFFECT Form EFFECT - Notice of Effectiveness:
11/16/2021 EFFECT Form EFFECT - Notice of Effectiveness:
11/09/2021 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accele...
Docs: "Amended and Restated Certificate of Incorporation of the Company",
"Amended and Restated Bylaws of the Company",
"First Supplemental Indenture, by and between Kadmon Holdings, Inc. and U.S. Bank National Association, as Trustee",
"Paris – November 9, 2021 - Sanofi announced today the completion of its acquisition of Kadmon Holdings, Inc. The acquisition further strengthens growth and expansion for the"
11/09/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/09/2021 S-8 POS Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments:
11/09/2021 POS AM Form POS AM - Post-Effective amendments for registration statement:
11/09/2021 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
11/05/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
11/04/2021 10-Q Quarterly Report for the period ended September 30, 2021
11/04/2021 8-K Quarterly results
Docs: "REZUROCK™ · On August 19, 2021 REZUROCK became commercially available for shipment to prescribed patients in the United States through a network of rare hematology/oncology specialty pharmacies and distributors o Execution of commercial launch remain underway, with a focus on generating awareness of REZUROCK's differentiated clinical value and facilitating market access o Experienced field team call on all target accounts, including engagement with 100% of the top 80 transplant centers, where ~90% of chronic graft-versus-host disease patients in the U.S. are treated o Strong sales performance and demand during initial launch period; $12.2 million net sales achieved in 3Q 2021 o The Company plans to present data on belumosudil at the 63rd American Society of Hematology Annual Me..."
10/27/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/27/2021 8-K Other Events  Interactive Data
10/21/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/21/2021 8-K Other Events  Interactive Data
10/04/2021 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
09/21/2021 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
09/17/2021 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
09/08/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
09/08/2021 8-K Quarterly results
08/05/2021 10-Q Quarterly Report for the period ended June 30, 2021
08/05/2021 8-K Quarterly results
07/19/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "U.S. FDA Grants Full Approval of REZUROCK™ for the Treatment of Patients with Chronic Graft-Versus-Host Disease"
05/28/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
05/12/2021 8-K Quarterly results
05/06/2021 10-Q Quarterly Report for the period ended March 31, 2021
05/06/2021 8-K Quarterly results
05/03/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/01/2021 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/01/2021 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/01/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
03/05/2021 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy